Cannabinoids in Gynecological Diseases Petra Luschnig, Rudolf Schicho Medical Cannabis & Cannabinoids, 2019, 2, 14-21 Doi : 10.1159/000499164 Abstract The endocannabinoid system (ECS) is a multifunctional homeostatic system involved in many physiological and pathological conditions. The ligands of the ECS are the endocannabinoids, whose actions are mimicked by exogenous cannabinoids, such as phytocannabinoids and synthetic cannabinoids. Responses to the ligands of the ECS are mediated by numerous receptors like the classical cannabinoid receptors (CB1 and CB2) as well as ECS-related receptors, e.g., G protein-coupled receptors 18 and 55 (GPR18 and GPR55), transient receptor potential ion channels, and nuclear peroxisome proliferator-activated receptors. The ECS regulatesalmost all levels of [...]
Lire la suiteGPR55-Mediated Effects in Colon Cancer Cell Lines Carina Hasenoehrl, David Feuersinger, Melanie Kienzl, Rudolf Schicho Medical Cannabis & Cannabinoids, 2019, 2, 22–28 Doi : 10.1159/000496356 Abstract The cannabinoid-responsive G protein-coupled receptor GPR55 and its endogenous ligand L-α lyso-phosphatidylinositol (LPI) have been reported to play a role in several cancers. A proliferation-enhancing effect of GPR55 has been described for several cancer cell lines and LPI has been found elevated in cancer patients. The aim of this study was to investigate whether GPR55 signaling had an effect on the proliferation of colon cancer cell lines. Using cell viability assays and Western blotting, we show that stable overexpression [...]
Lire la suiteThe Reemergence of Ketamine for Treatment in Critically Ill Adults Kimberly P. Hurth, Kristen B. Thomas, Michael A. Rudoni Critical Care Medicine, 2020,1-13. Doi : 10.1097/CCM.0000000000004335 Objectives : To assess the evidence and discuss the risks and clinical relevance of ketamine for the treatment of various disease states impacting the adult critically ill population. Data Sources : A literature review was performed using PubMed evaluating primary literature published until August 2018. Study Selection : Case reports, observational studies (cohort, case-control), and randomized controlled trials involving patients 18 years and older in a nonperioperative setting using either IV or intramuscular ketamine were included for analysis. Uses of [...]
Lire la suiteThe 2nd International Annual Congress on Controversies on Cannabis-Based Medicines (Med-Cannabis 2019) Barcelona, Spain, May 23–24, 2019 Abstracts Congress Chairs: Prof. Dr. Med. Winfried Häuser, Klinikum Saarbrücken, Germany Dr. Silviu Brill, Tel Aviv Medical Center, Israel Medical Cannabis & Cannabinoids, 2019, 2, 69–83 Published online: May 13, 2019 Doi : 10.1159/000500623 KRAGER : Basel · Freiburg · Paris · London · New York · Chennai · New Delhi · Bangkok · Beijing · Shanghai · Tokyo · Kuala Lumpur · Singapore · Sydney © 2019 The Author(s) Published by S. Karger AG, Basel E-Mail karger@karger.com www.karger.com/mca P-01 Cannabis and Metals: Soils Need to be Controlled Yann Barguil , Laura Chiaradia Biochemistry and Toxicology Laboratory, Gaston Bourret Territorial Hospital [...]
Lire la suite4th International Medical Cannabis Conference (CannX 2019) Tel Aviv, Israel, September 9–10, 2019 Abstracts Scientific Committee Dr. Adi Aran Director of the Neuro-Pediatric Unit, Shaare Zedek Medical Center, Israel Prof. Gil Bar-Sela Head, Cancer Center, Emek Medical Center Afula, Israel Dr. Nirit Bernstein Principle Research Scientist, Plant Physiology and Nutrition Institute of Soil Water and Environmental Sciences, Volcani Center, Israel Prof. Lumir Hanus Chief Scientist, Lumir Lab, Associate Professor, Palacký University, Jerusalem Biotechnology Park, Hebrew University, Ein Kerem Campus, Senior Fellow, IEHP, Thomas Jefferson University, Philadelphia, USA, Professor Chaver and Research Fellow, Hebrew University (Ret.) Institute for Drug Research, School of Pharmacy, Faculty of Medicine, Hebrew University, Israel Dr. Shaul Lev-Ran, MHA Deputy Director, Lev Hasharon Medical Center [...]
Lire la suiteThe Intricate Influence of the Placebo Effect on Medical Cannabis and Cannabinoids Jürg Gertsch Medical Cannabis Cannabinoids, 2018, 1, 60–64 Doi : 10.1159/000489291 Abstract The botanical drug cannabis flos (inflorescence of Cannabis sativa L.) has a unique popular status as being a potent recreational drug and bona fide universal remedy (panacea). Generally, cannabinoids exert therapeutic effects in a broad range of pathophysiologies related to inflammation, pain, metabolic and stress-related conditions in preclinical animal models. However, the translation of such data to humans still lacks an evidence-based foundation. Motivated by the booming cannabis manufacturing industry and the increasing worldwide self-therapy by patients, there are cumulative accounts [...]
Lire la suiteCannabis (Marijuana) : Psychoactive Properties, Addiction, Therapeutic Uses, and Toxicity Sumanasekera W.K. and Spio K. Journal of Addictive Behaviors, Therapy and Rehabilitation, 2016, 5, 2, 1-9. Doi : 10.4172/2324-9005.10001562016 Abstract Background and Objectives : To analyze the existing literature on cannabis (marijuana) under several sub topics; history of use, addiction, mechanism of action, therapeutic uses, and adverse effects. Methods : A comprehensive literature search was conducted. Data sources include original research articles, systematic reviews and meta- analysis, and web-based references such as Drug strategy monographs and Merck Index. Data bases such as PubMed and Cinhal was used. References were from 1979 -2016. Hypothesis : Based on the [...]
Lire la suiteLes effets antidépresseurs de la kétamine élucidés Utilisée de longue date comme anesthésique, cette molécule vient d’être autorisée comme antidépresseur aux Etats-Unis. Par Florence Rosier Publié le 16 avril 2019 à 06h00 - https://www.lemonde.fr/sciences/article/2019/04/16/les-effets-antidepresseurs-de-la-ketamine-elucides_5450737_1650684.html La kétamine est une molécule à surprises. Et pas seulement pour ceux qui recherchent ses effets hallucinogènes en la détournant de ses applications médicales. Depuis les années 1970, elle est largement utilisée comme anesthésique à usage humain ou vétérinaire. Mais elle est aussi dotée de puissants effets antidépresseurs, découverts voici plus de vingt ans. Or, ceux-ci viennent d’être doublement reconnus : au plan réglementaire, par la toute-puissante agence américaine du médicament (FDA) ; [...]
Lire la suiteBibliographie : Cannabinoïdes et exposition prénatale Dr Christian SUEUR, GRECC, avril 2020.
Lire la suiteAltered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment Tibor Stark, Martina Di Bartolomeo, Roberta Di Marco, Eva Drazanova, Chiara Bianca Maria Platania, Fabio Arturo Iannotti, Jana Ruda-Kucerova, Claudio D'Addario, Lucie Kratka, Vladimir Pekarik, Fabiana Piscitelli, Zuzana Babinska, Julia Fedotova, Giovanni Giurdanella, Salvatore Salomone, Alexandra Sulcova, Claudio Bucolo, Carsten T.Wotjak, Zenon Starcuk Jr, Filippo Drago, Raphael Mechoulam, Vincenzo Di Marzo, Vincenzo Micale Biochemical Pharmacology, April 2020, 1-12. doi : 10.1016/j.bcp.2020.114004 Un excellent article international (République Tchèque, Allemagne, Italy, Russie, Israel, Canada), avec la plus grande plume de la recherche sur les cannabinoïdes (Mechoulam, Di Marzo...) qui [...]
Lire la suite